MBOT

Business Context and Reporting Period

Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2003
Business Overview: The company is engaged in the research and development of human therapeutic products, specifically focusing on stem cell technology for neural and liver diseases. It has not commercialized any products and relies on external financing, grants, and collaborative arrangements to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by approximately 47% to $59,000, driven primarily by a reduction in grant revenue from the NIH ($56,250 in Q1 2003 vs. $111,299 in Q1 2002).
• Expense Reductions:
  • R&D Expenses: Decreased 13% to $1.34 million, attributed to a cost reduction program (25% staff reduction) and a lease amendment reducing rent expenses.
  • G&A Expenses: Decreased 20% to $1.07 million, also due to the cost reduction program and lower rent.
• Liquidity Position: Cash and cash equivalents dropped significantly from $4.24 million at year-end 2002 to $1.55 million at March 31, 2003, reflecting a net cash burn of $2.69 million for the quarter.
• Debt and Leases: The company maintains significant capital lease obligations ($2.26 million outstanding principal) and operating lease commitments, particularly for facilities in Rhode Island which are partially subleased.

Outlook, Risks, and Subsequent Events

• Going Concern: Management states that capital resources at the end of Q1 were insufficient to fund operations through Q2 2003. However, subsequent financing agreements are expected to fund operations into 2004.
• Subsequent Financing (May 2003):
  • Entered a stock purchase agreement with Riverview Group to sell 4 million shares for $6.5 million ($1.625/share).
  • Issued a 2-year warrant to purchase 1.898 million shares at $1.50/share.
  • Drew down $375,000 on an existing equity line with Sativum Investments.
• Preferred Stock Conversion (April 2003): Agreed to reduce the conversion price of 3% Cumulative Convertible Preferred Stock to $0.80/share. Riverview converted $2 million face value of preferred stock into common stock, relieving the company of a mandatory cash redemption obligation due in December 2003. This will result in a deemed dividend of approximately $1 million in Q2 2003.
• NASDAQ Compliance Risks:
  • Stockholders' Equity: Equity of $1.2 million was below the $2.5 million minimum requirement. Management expects the May 2003 financing to restore compliance.
  • Bid Price: Stock closed below $1.00 for 30 consecutive days. The company was granted 180 days (until Oct 20, 2003) to regain compliance.
• Scientific Progress: Preclinical studies in animal models for Batten Disease and Spinal Cord Injury showed proof of principle, but no human clinical trials have been completed.

Investor Verification Checklist

• Closing of May 2003 Financing: Verify if the $6.5 million private placement with Riverview Group has closed and funds have been received.
• NASDAQ Status: Confirm current compliance status regarding minimum stockholders' equity and minimum bid price requirements.
• Rhode Island Facility Obligations: Assess the timeline and likelihood of subleasing or selling the remaining interests in the Rhode Island facilities to mitigate the ~$1 million annual net lease obligation.
• Q2 2003 Deemed Dividend: Monitor the impact of the ~$1 million deemed dividend on Q2 2003 net loss and equity.
• Grant Renewals: Verify the status of NIH grants, as revenue is heavily dependent on these non-recurring or milestone-based funds.